Sensus Healthcare Balances Weak Quarter With Growth Catalysts

Sensus Healthcare, Inc. ((SRTS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Sensus Healthcare’s latest earnings call painted a cautiously optimistic picture for investors, blending harsh near‑term realities with tangible strategic progress. Management acknowledged a steep revenue decline and margin pressure but highlighted catalysts like new reimbursement codes, rising treatment volumes, and growing recurring revenue that they believe put the company on a path toward profitability.

Dedicated CPT Codes Clarify Reimbursement Landscape

New dedicated CPT codes for superficial radiotherapy, effective in early 2026, were a central positive theme on the call. Executives said the clearer coding framework is already boosting physician confidence and should simplify billing for dermatology practices, laying the groundwork for broader adoption of Sensus’s SRT systems over the next several years.

Tripled Reimbursement Improves Physician Economics

Management underscored that the per‑fraction delivery code used with their SRT systems has increased by roughly 300%. This sharp improvement in reimbursement economics is driving more inquiries and a healthier pipeline, as dermatologists see a faster return on investment and more attractive margins for non‑surgical skin cancer treatments.

Steady Shipments Support Nearly 1,000-System Base

In the first quarter, Sensus shipped 14 SRT systems, matching the prior quarter’s level and demonstrating some resilience in demand. With an installed base now around 965 systems worldwide, management believes even modest utilization gains can meaningfully lift recurring revenue as the platform footprint continues to expand.

Utilization and Recurring Revenue Gain Momentum

Treatment volumes rose 8% year over year, and the company now counts 18 active FDA sites with nine more awaiting activation. Sensus emphasized that growing revenue from rentals, service, and utilization‑based arrangements is key to smoothing out the lumpiness of capital sales and building a more predictable business model.

SensusLink Software Targets New High-Margin Revenue

The company’s new SensusLink software platform is live at several accounts and is designed to create incremental, high‑margin recurring revenue streams. By enabling billing for radiation physics consult codes and supporting weekly reimbursement of roughly $93.85 per patient protocol, the software could materially enhance lifetime revenue per installed system.

Shift Toward Purchases Lowers Customer Breakeven

Roughly 70% of Q1 system shipments were outright purchases rather than FDA arrangements, marking a notable shift in customer behavior. Management said the average breakeven for buyers is now around two patients per month, which they believe will encourage earlier ownership decisions and help accelerate recognized revenue.

Solid Balance Sheet Provides Strategic Flexibility

Sensus ended the quarter with $18.3 million in cash and no debt, giving the company breathing room as it navigates the transition to a more recurring model. Executives framed this balance sheet strength as a competitive advantage, allowing continued investment in commercial expansion without resorting to highly dilutive financing.

Cost Discipline Evident in Lower Operating Expenses

Operating expenses moved lower across the board, reflecting a deliberate push to control costs during a difficult revenue period. General and administrative spending dipped to $2.0 million, while selling and marketing fell to $1.7 million and R&D to $1.6 million, helping to partially offset the impact of weaker gross profit.

Pipeline Strengthened by Conferences and Financing Options

Management reported strong lead generation from major dermatology conferences, including high‑profile events that brought them closer to independent practices and larger networks. To convert more of those leads, Sensus launched its own financial services offering, aimed at providing flexible financing solutions to both hospital systems and private equity‑backed platforms.

Revenue Contracts Sharply Without Key Customer

First‑quarter revenue fell to $3.4 million from $8.3 million a year earlier, a drop of roughly 59%. The decline was primarily attributed to the absence of purchases from Sensus’s historically largest customer, and management explicitly noted that current‑year modeling does not assume a return from that account.

Gross Margin Compression Weighs on Profitability

Gross profit shrank to $1.0 million from $4.4 million, driving gross margin down to 29.2% from 52.2%. The company blamed a mix shift toward international shipments with lower average selling prices, along with Fair Deal and rental placements that are recognized over time rather than upfront.

Adjusted EBITDA Loss Widens Despite Cost Cuts

Adjusted EBITDA deteriorated to a loss of $4.2 million compared with a $2.5 million loss in the prior year period. The larger deficit underscores that margin pressure and lower revenue more than offset operating expense reductions, leaving Sensus still some distance from sustainable profitability.

Net Loss Stable, But Progress Still Limited

The bottom line showed a net loss of $2.6 million, or $0.16 per share, essentially flat year over year. While this stability might reassure some investors, it also signals that the company’s strategic initiatives have yet to translate into meaningful near‑term earnings improvement.

Revenue Recognition and Mix Create Short-Term Headwinds

A growing share of placements under Fair Deal and rental structures means more revenue is recognized over the life of the contract rather than at shipment, dampening near‑term results. Combined with a higher proportion of lower‑priced international systems, this mix shift is pressuring both reported revenue and margins in the transition period.

Inventory Build Raises Working Capital Questions

Inventory climbed to $16.5 million from $14.6 million, a roughly 13% increase in just one quarter. Management framed the build as preparation for expected demand, but investors will be watching closely to ensure that pipeline conversion keeps pace and that capital is not tied up in slow‑moving stock.

Customer Concentration Adds an Element of Uncertainty

The absence of purchases from the company’s largest historical customer was a notable swing factor in the quarter. Management has deliberately excluded this account from current guidance, suggesting any return would be upside, but the situation highlights ongoing revenue concentration risk during the transition.

Guidance Points to Sequential Improvement and Profitability

Looking ahead, Sensus guided that second‑quarter revenue should exceed the $3.4 million posted in Q1, with the back half of the year surpassing the first half. Management reiterated a goal of building toward full‑year profitability through sequential quarter‑over‑quarter improvement, supported by expanding recurring revenue, broader SensusLink deployment, and the benefits of enhanced reimbursement.

Sensus Healthcare’s earnings call left investors with a complex narrative of short‑term pain and potentially significant long‑term gain. While revenue declines, margin compression, and a wider adjusted EBITDA loss signal real challenges, the combination of stronger reimbursement, growing utilization, and a solid balance sheet suggests the company may be better positioned than current results alone would imply.